{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T15:38:13Z","timestamp":1777217893595,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11892-017-0838-7","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T11:44:15Z","timestamp":1485949455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Diabetes in Patients With Acromegaly"],"prefix":"10.1007","volume":"17","author":[{"given":"A. M.","family":"Hannon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sherlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"issue":"3","key":"838_CR1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","volume":"31","author":"M Sherlock","year":"2010","unstructured":"Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301\u201342.","journal-title":"Endocr Rev"},{"issue":"1","key":"838_CR2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","volume":"17","author":"O Alexopoulou","year":"2014","unstructured":"Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014;17(1):81\u20139.","journal-title":"Pituitary"},{"issue":"5","key":"838_CR3","first-page":"1012","volume":"74","author":"N Moller","year":"1992","unstructured":"Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE, et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab. 1992;74(5):1012\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"838_CR4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/BF03345491","volume":"25","author":"C Ronchi","year":"2002","unstructured":"Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Investig. 2002;25(6):502\u20137.","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"838_CR5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jc.2013-3264","volume":"99","author":"A Thankamony","year":"2014","unstructured":"Thankamony A, Tossavainen PH, Sleigh A, Acerini C, Elleri D, Dalton RN, et al. Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes. J Clin Endocrinol Metab. 2014;99(2):639\u201347.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"838_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-16-0117","volume":"175","author":"J Dal","year":"2016","unstructured":"Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175(3):181\u201390.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"838_CR7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-12-0084","volume":"167","author":"M Arosio","year":"2012","unstructured":"Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167(2):189\u201398.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"838_CR8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 2011;164(6):877\u201384.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"838_CR9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/EC-14-0021","volume":"3","author":"AV Dreval","year":"2014","unstructured":"Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS, Barsukov IA, et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connections. 2014;3(2):93\u20138.","journal-title":"Endocr Connections"},{"issue":"4","key":"838_CR10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11102-012-0447-z","volume":"16","author":"S Siegel","year":"2013","unstructured":"Siegel S, Streetz-van der Werf C, Schott JS, Nolte K, Karges W, Kreitschmann-Andermahr I. Diagnostic delay is associated with psychosocial impairment in acromegaly. Pituitary. 2013;16(4):507\u201314.","journal-title":"Pituitary"},{"issue":"1","key":"838_CR11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1507\/endocrj.EJ14-0254","volume":"62","author":"K Suda","year":"2015","unstructured":"Suda K, Fukuoka H, Iguchi G, Hirota Y, Nishizawa H, Bando H, et al. The prevalence of acromegaly in hospitalized patients with type 2 diabetes. Endocr J. 2015;62(1):53\u20139.","journal-title":"Endocr J"},{"issue":"6","key":"838_CR12","first-page":"717","volume":"19","author":"A Giustina","year":"1998","unstructured":"Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717\u201397.","journal-title":"Endocr Rev"},{"key":"838_CR13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000342573","volume":"24","author":"A Vottero","year":"2013","unstructured":"Vottero A, Guzzetti C, Loche S. New aspects of the physiology of the GH-IGF-1 axis. Endocr Dev. 2013;24:96\u2013105.","journal-title":"Endocr Dev"},{"issue":"6 Pt 1","key":"838_CR14","first-page":"E846","volume":"260","author":"M Boni-Schnetzler","year":"1991","unstructured":"Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Phys. 1991;260(6 Pt 1):E846\u201351.","journal-title":"Am J Phys"},{"issue":"1 Pt 1","key":"838_CR15","first-page":"E86","volume":"258","author":"N Moller","year":"1990","unstructured":"Moller N, Jorgensen JO, Schmitz O, Moller J, Christiansen J, Alberti KG, et al. Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Phys. 1990;258(1 Pt 1):E86\u201391.","journal-title":"Am J Phys"},{"issue":"2","key":"838_CR16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N Moller","year":"2009","unstructured":"\u2022\u2022 Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152\u201377. Excellent overview of metabolic effects of GH.","journal-title":"Endocr Rev"},{"issue":"5","key":"838_CR17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","volume":"52","author":"S Kasayama","year":"2000","unstructured":"Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol. 2000;52(5):549\u201355.","journal-title":"Clin Endocrinol"},{"issue":"11","key":"838_CR18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/BF00873216","volume":"29","author":"S Karlander","year":"1986","unstructured":"Karlander S, Vranic M, Efendic S. Increased glucose turnover and glucose cycling in acromegalic patients with normal glucose tolerance. Diabetologia. 1986;29(11):778\u201383.","journal-title":"Diabetologia"},{"issue":"7621","key":"838_CR19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(69)90327-4","volume":"2","author":"RS Elkeles","year":"1969","unstructured":"Elkeles RS, Wright AD, Lowy C, Fraser TR. Serum-insulin in acromegaly. Lancet. 1969;2(7621):615\u20138.","journal-title":"Lancet"},{"issue":"6","key":"838_CR20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/db06-0299","volume":"56","author":"JP Rincon del","year":"2007","unstructured":"del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, et al. Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes. 2007;56(6):1638\u201346.","journal-title":"Diabetes"},{"issue":"6","key":"838_CR21","doi-asserted-by":"crossref","first-page":"E1360","DOI":"10.1152\/ajpendo.00335.2001","volume":"282","author":"T Pratipanawatr","year":"2002","unstructured":"Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K, et al. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2002;282(6):E1360\u20138.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"838_CR22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11102-012-0396-6","volume":"16","author":"D Niculescu","year":"2013","unstructured":"Niculescu D, Purice M, Coculescu M. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary. 2013;16(2):168\u201374.","journal-title":"Pituitary"},{"issue":"6","key":"838_CR23","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s11102-015-0657-2","volume":"18","author":"TJ Reid","year":"2015","unstructured":"Reid TJ, Jin Z, Shen W, Reyes-Vidal CM, Fernandez JC, Bruce JN, et al. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary. 2015;18(6):808\u201319.","journal-title":"Pituitary"},{"issue":"4","key":"838_CR24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1210\/jc.2007-2104","volume":"93","author":"O Alexopoulou","year":"2008","unstructured":"\u2022 Alexopoulou O, Bex M, Abs R, T\u2019Sjoen G, Velkeniers B, Maiter D. Divergence between growth hormone and insulin-like growth factor-1 concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab. 2008;93(4):1324\u201330. A significant proportion of patients have divergent results at follow up\u2014clinical significance of this remains unclear.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"838_CR25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667\u201374.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"838_CR26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2265.1992.tb02902.x","volume":"36","author":"KD Hopkins","year":"1992","unstructured":"Hopkins KD, Holdaway IM. Insulin secretion and insulin-like growth factor-I levels in active and controlled acromegaly. Clin Endocrinol. 1992;36(1):53\u20137.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"838_CR27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1015713732717","volume":"13","author":"D Baris","year":"2002","unstructured":"Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5):395\u2013400.","journal-title":"Cancer Causes Control"},{"issue":"5","key":"838_CR28","doi-asserted-by":"crossref","first-page":"e0127276","DOI":"10.1371\/journal.pone.0127276","volume":"10","author":"S Cheng","year":"2015","unstructured":"Cheng S, Gomez K, Serri O, Chik C, Ezzat S. The role of diabetes in acromegaly associated neoplasia. PLoS One. 2015;10(5):e0127276.","journal-title":"PLoS One"},{"key":"838_CR29","doi-asserted-by":"crossref","unstructured":"Wen-Ko C, Szu-Tah C, Feng-Hsuan L, Chen-Nen C, Ming-Hsu W, Jen-Der L. The impact of diabetes mellitus on the survival of patients with acromegaly. Endokrynol Pol. 2016;67(5):501-6.","DOI":"10.5603\/EP.a2016.0031"},{"issue":"11","key":"838_CR30","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws Jr ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"838_CR31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/EJE-10-1096","volume":"164","author":"Y Kinoshita","year":"2011","unstructured":"Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K, et al. Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur J Endocrinol. 2011;164(4):467\u201373.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"838_CR32","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282\u201390.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"838_CR33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"\u2022 Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500\u20138. Overview of the studies that assessed glucose meatbolism in SSAs.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"838_CR34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology. 2004;80 Suppl 1:47\u201350.","journal-title":"Neuroendocrinology"},{"issue":"11","key":"838_CR35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"838_CR36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine. 2016;53(1):210\u20139.","journal-title":"Endocrine"},{"issue":"10","key":"838_CR37","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0006-2952(99)00010-6","volume":"57","author":"Y Zambre","year":"1999","unstructured":"Zambre Y, Ling Z, Chen MC, Hou X, Woon CW, Culler M, et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol. 1999;57(10):1159\u201364.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"838_CR38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1210\/jc.2006-1578","volume":"92","author":"V Singh","year":"2007","unstructured":"Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92(2):673\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"838_CR39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","volume":"103","author":"A Breitschaft","year":"2014","unstructured":"Breitschaft A, Hu K, Hermosillo Resendiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014;103(3):458\u201365.","journal-title":"Diabetes Res Clin Pract"},{"key":"838_CR40","unstructured":"American Diabetes Association. Standards of medical care in diabetes 2016 [updated 2016; cited 2016 october 22nd]. Available from: http:\/\/care.diabetesjournals.org\/content\/39\/Supplement_1 ."},{"issue":"16","key":"838_CR41","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"838_CR42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-13-0032","volume":"169","author":"C Urbani","year":"2013","unstructured":"Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, et al. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol. 2013;169(1):99\u2013108.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"838_CR43","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","volume":"94","author":"CE Higham","year":"2009","unstructured":"Higham CE, Rowles S, Russell-Jones D, Umpleby AM, Trainer PJ. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab. 2009;94(7):2459\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"838_CR44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-13-0438","volume":"171","author":"M Droste","year":"2014","unstructured":"Droste M, Domberg J, Buchfelder M, Mann K, Schwanke A, Stalla G, et al. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol. 2014;171(1):59\u201368.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"838_CR45","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1210\/jc.2008-1420","volume":"94","author":"M Sherlock","year":"2009","unstructured":"Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, et al. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab. 2009;94(4):1255\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"838_CR46","first-page":"372","volume":"71","author":"H Rau","year":"1993","unstructured":"Rau H, Althoff PH, Schmidt K, Badenhoop K, Usadel KH. Bromocriptine treatment over 12\u00a0years in acromegaly: effect on glucose tolerance and insulin secretion. Clin Investig. 1993;71(5):372\u20138.","journal-title":"Clin Investig"},{"issue":"8","key":"838_CR47","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","volume":"23","author":"H Pijl","year":"2000","unstructured":"Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23(8):1154\u201361.","journal-title":"Diabetes Care"},{"issue":"8","key":"838_CR48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1055\/s-2005-865772","volume":"113","author":"K Krzyzanowska","year":"2005","unstructured":"Krzyzanowska K, Schnack C, Mittermayer F, Kopp HP, Hofer M, Kann T, et al. High prevalence of abnormal circadian blood pressure regulation and impaired glucose tolerance in adults with hypopituitarism. Exp Clin Endocrinol Diabetes. 2005;113(8):430\u20134.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"838_CR49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2265.1995.tb02602.x","volume":"42","author":"KA Al-Shoumer","year":"1995","unstructured":"Al-Shoumer KA, Beshyah SA, Niththyananthan R, Johnston DG. Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin Endocrinol. 1995;42(1):85\u201390.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"838_CR50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jc.2013-2394","volume":"99","author":"C Gazzaruso","year":"2014","unstructured":"Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH\u2014an update. J Clin Endocrinol Metab. 2014;99(1):18\u201329.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"838_CR51","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2265.2012.04361.x","volume":"77","author":"E Lin","year":"2012","unstructured":"Lin E, Wexler TL, Nachtigall L, Tritos N, Swearingen B, Hemphill L, et al. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clin Endocrinol. 2012;77(3):430\u20138.","journal-title":"Clin Endocrinol"},{"issue":"11","key":"838_CR52","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1210\/jc.2012-2477","volume":"97","author":"C Giavoli","year":"2012","unstructured":"Giavoli C, Profka E, Verrua E, Ronchi CL, Ferrante E, Bergamaschi S, et al. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. J Clin Endocrinol Metab. 2012;97(11):3983\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"838_CR53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","volume":"16","author":"S Melmed","year":"2013","unstructured":"Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294\u2013302.","journal-title":"Pituitary"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-017-0838-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-017-0838-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-017-0838-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T04:52:30Z","timestamp":1568782350000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-017-0838-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1007\/s11892-017-0838-7","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"article-number":"8"}}